Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study (ASGARD)
A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease
Sponsor: Anglia Ruskin University
Listed as NCT02578394, this PHASE2/PHASE3 trial focuses on Chronic Kidney Diseases and Gout and remains completed. Sponsored by Anglia Ruskin University, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anglia Ruskin University
- Mid and South Essex NHS Foundation Trust
- National Institute for Health Research, United Kingdom
- University of East Anglia
- University of Essex
For direct contact, visit the study record on ClinicalTrials.gov .